高级检索
当前位置: 首页 > 详情页

Circulating fibroblast growth factor 21 as a potential biomarker for missed abortion in humans.

文献详情

资源类型:
Pubmed体系:
机构: [1]The Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, People’s Republic of China [2]Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, People’s Republic of China [3]State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Hong Kong SAR, People’s Republic of China [4]Department of Medicine, the University of Hong Kong, Hong Kong SAR, People’s Republic of China [5]Joint Laboratory between Guangdong and Hong Kong on Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China [6]Guangdong Research Center of Metabolic Diseases of Integrated Western and Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China [7]Department of Pharmaceutical and Pharmacy, the University of Hong Kong, Hong Kong SAR, People’s Republic of China [8]School of Clinical Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China [9]School of Biomedicine Science, Shenzhen University, Shenzhen, People’s Republic of China
出处:
ISSN:

关键词: blood-based biomarkers FGF21 FABP4 missed abortion reproductive endocrinology

摘要:
To investigate whether serum levels of fibroblast growth factor 21 (FGF21) and fatty acid-binding protein-4 (FABP4) are associated with missed abortion (MA) in humans.Cross-sectional study.University-affiliated hospital.Patients with MA at 8-12 weeks of gestation.None.Serum levels of FGF21 and FABP4 were tested by enzyme-linked immunosorbent assay. Placental samples were collected during dilation and curettage surgery, and the expression of FGF21 and its related genes were measured using quantitative polymerase chain reaction.In the discovery cohort, 78 patients with MA and 79 healthy pregnant women matched for maternal age and body mass index were nested from a prospective cohort. Circulating levels of FGF21 and FABP4 were significantly and independently elevated in patients with MA relative to the levels in the healthy controls. A single measurement of FGF21 serum level effectively discriminated MA with an area under the receiver operating characteristics curve of 0.80 (95% confidence interval: 0.73-0.87). Importantly, in our external validation cohort that comprised subjects with MA (n = 34) or induced abortion (n = 27), the FGF21 serum levels achieved an area under the receiver operating characteristics curve of 0.85 (95% confidence interval: 0.75-0.96) when identifying those with MA. Nevertheless, expression of FGF21 in the placenta was not associated with its serum concentration. Placental tissues from patients with MA exhibited impaired FGF21 signaling.Our results suggested that serum levels of FGF21 and FABP4 were associated with MA. Circulating FGF21 may serve as a potential biomarker for the recognition of MA.Copyright © 2021 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类 | 2 区 医学
小类 | 1 区 妇产科学 1 区 生殖生物学
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 妇产科学 1 区 生殖生物学
第一作者:
第一作者机构: [1]The Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, People’s Republic of China [2]Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, People’s Republic of China
共同第一作者:
通讯作者:
通讯机构: [3]State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Hong Kong SAR, People’s Republic of China [4]Department of Medicine, the University of Hong Kong, Hong Kong SAR, People’s Republic of China [*1]Department of Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Room 833A, 8th Floor, Sassoon RD 21, Hong Kong SAR, People’s Republic of China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号